$93.50
1.05%
Nasdaq, Aug 29, 10:00 pm CET

ANI Pharmaceuticals, Inc. Stock price

$93.50
+29.30 45.64% 1M
+31.61 51.07% 6M
+38.22 69.14% YTD
+31.05 49.72% 1Y
+56.32 151.48% 3Y
+62.14 198.15% 5Y
+44.73 91.72% 10Y
-49.42 34.58% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.97 1.05%

Key metrics

Basic
Market capitalization
$2.0b
Enterprise Value
$2.4b
Net debt
$398.1m
Cash
$223.5m
Shares outstanding
21.7m
Valuation (TTM | estimate)
P/E
negative | 12.7
P/S
2.7 | 2.4
EV/Sales
3.3 | 2.8
EV/FCF
19.3
P/B
4.4
Financial Health
Equity Ratio
33.4%
Return on Equity
-4.7%
ROCE
2.1%
ROIC
1.6%
Debt/Equity
1.3
Financials (TTM | estimate)
Revenue
$747.4m | $856.0m
EBITDA
$107.3m | $206.1m
EBIT
$22.8m | $174.9m
Net Income
$-14.2m | $160.2m
Free Cash Flow
$125.4m
Growth (TTM | estimate)
Revenue
10.5% | 39.3%
EBITDA
-20.0% | 192.0%
EBIT
-61.8% | 6,057.4%
Net Income
-134.9% | 895.0%
Free Cash Flow
26.0%
Margin (TTM | estimate)
Gross
61.1%
EBITDA
14.4% | 24.1%
EBIT
3.1%
Net
-1.9% | 18.7%
Free Cash Flow
16.8%
More
EPS
$-0.7
FCF per Share
$5.8
Short interest
12.8%
Employees
897
Rev per Employee
$680.0k
Show more

Is ANI Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

ANI Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a ANI Pharmaceuticals, Inc. forecast:

Buy
86%
Hold
14%

Financial data from ANI Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
747 747
11% 11%
100%
- Direct Costs 291 291
13% 13%
39%
456 456
9% 9%
61%
- Selling and Administrative Expenses 307 307
30% 30%
41%
- Research and Development Expense 54 54
9% 9%
7%
107 107
20% 20%
14%
- Depreciation and Amortization 85 85
14% 14%
11%
EBIT (Operating Income) EBIT 23 23
62% 62%
3%
Net Profit -14 -14
135% 135%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about ANI Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ANI Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
8 days ago
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company's executive leadership team will present at two upcoming investor conferences as follows:
Neutral
Seeking Alpha
25 days ago
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - President, CEO & Director Stephen P.
Neutral
GlobeNewsWire
25 days ago
BAUDETTE, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2025.
More ANI Pharmaceuticals, Inc. News

Company Profile

ANI Pharmaceuticals, Inc. is a pharmaceutical company, which engages in developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended release and combination products. The company was founded on August 29, 1996 and is headquartered in Baudette, MN.

Head office United States
CEO Nikhil Lalwani
Employees 897
Founded 1996
Website www.anipharmaceuticals.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today